loading page

Omicron breakthrough infections in wild-type SARS-CoV-2 vaccinees elicit high levels of neutralizing antibodies against pangolin coronavirus GX_P2V
  • +8
  • Lihua Song,
  • Shanshan Lu,
  • Shengdong Luo,
  • Bingke Bai,
  • Zhenping Fan,
  • Bixia Hong,
  • Wen Xu,
  • Hongbin Ma,
  • Wei-Wei Chen,
  • Huahao Fan,
  • Yigang Tong
Lihua Song
Beijing University of Chemical Technology College of Life Science and Technology

Corresponding Author:[email protected]

Author Profile
Shanshan Lu
Beijing University of Chemical Technology College of Life Science and Technology
Author Profile
Shengdong Luo
5th Medical Center of Chinese PLA General Hospital
Author Profile
Bingke Bai
5th Medical Center of Chinese PLA General Hospital
Author Profile
Zhenping Fan
5th Medical Center of Chinese PLA General Hospital
Author Profile
Bixia Hong
Beijing University of Chemical Technology College of Life Science and Technology
Author Profile
Wen Xu
5th Medical Center of Chinese PLA General Hospital
Author Profile
Hongbin Ma
5th Medical Center of Chinese PLA General Hospital
Author Profile
Wei-Wei Chen
5th Medical Center of Chinese PLA General Hospital
Author Profile
Huahao Fan
Beijing University of Chemical Technology College of Life Science and Technology
Author Profile
Yigang Tong
Beijing University of Chemical Technology College of Life Science and Technology
Author Profile

Abstract

Omicron BF.7 became the predominant SARS-CoV-2 variant in Beijing after the adjustment of COVID-19 response strategies in December 2022. The ability of antibodies elicited by BF.7 infection to cross-react with SARS-CoV-2-like viruses is unknown. This study aimed to investigate the cross-reactive neutralizing antibodies against SARS-CoV-2-related pangolin coronavirus GX_P2V in sera from vaccinated and/or SARS-CoV-2 infected individuals. All vaccinated individuals who recovered from Omicron BF.7 breakthrough infections exhibited substantially higher levels of neutralizing antibodies against GX_P2V among collected subject populations (geometric mean titer [GMT] = 362). Uninfected individuals who received four-mixed-dose vaccines also demonstrated higher levels of neutralizing antibodies (GMT = 44) against GX_P2V than those who received two- or three-dose vaccines and those who recovered from wild type SARS-CoV-2. This finding highlights the significance of prior and hybrid booster vaccinations with wild-type SARS-CoV-2 vaccines in generating potent cross-protective immunity against future spillovers of SARS-CoV-2-like viruses.
10 Apr 2023Submitted to Journal of Medical Virology
10 Apr 2023Submission Checks Completed
10 Apr 2023Assigned to Editor
10 Apr 2023Review(s) Completed, Editorial Evaluation Pending
18 Apr 2023Reviewer(s) Assigned
05 May 2023Editorial Decision: Revise Minor
14 May 20231st Revision Received
16 May 2023Submission Checks Completed
16 May 2023Assigned to Editor
16 May 2023Review(s) Completed, Editorial Evaluation Pending
22 May 2023Reviewer(s) Assigned
06 Jun 2023Editorial Decision: Revise Minor
19 Jun 20232nd Revision Received
20 Jun 2023Submission Checks Completed
20 Jun 2023Assigned to Editor
20 Jun 2023Review(s) Completed, Editorial Evaluation Pending
20 Jun 2023Reviewer(s) Assigned
10 Jul 2023Editorial Decision: Revise Minor
12 Jul 20233rd Revision Received
13 Jul 2023Submission Checks Completed
13 Jul 2023Assigned to Editor
13 Jul 2023Review(s) Completed, Editorial Evaluation Pending
19 Jul 2023Reviewer(s) Assigned
31 Jul 2023Editorial Decision: Accept